secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001708599-25-000058
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina appoints ex-Karuna CMO Brannan to board; director Gross departs
----------------------------------------------------------------------

- Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.
- Brannan led clinical strategy for KarXT, first new schizophrenia mechanism in >30 years, key to Karuna's $14B BMS acquisition.
- Remy Gross departed board effective May 22, 2025; no disagreement, stays as consultant.
- Filed certificate of correction to Series A Preferred Stock to add conversion price adjustment reference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/ser-20250522.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer